Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 2/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.44 |
| ▸ | SRR | Q9GZT4 | 3/20 | 0.44 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.43 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.42 |
| ▸ | PSAT1 | Q9Y617 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1136238 | 1.00 | LAP3 (0.52) | LAP3SLC7A5RNPEPSRRCACNA2D1 | |
| SCHEMBL11789757 | 1.00 | LAP3 (0.52) | LAP3SLC7A5RNPEPSRRCACNA2D1 | |
| Hydrochloric Acid SCHEMBL11385922 | 0.98 | LAP3 (0.50) | LAP3SLC7A5RNPEPSRRCACNA2D1 | |
| Hydrochloric Acid SCHEMBL10486450 | 0.98 | LAP3 (0.50) | LAP3SLC7A5RNPEPSRRCACNA2D1 | |
| SCHEMBL13461523 | 0.78 | LAP3 (0.48) | LAP3SLC7A5RNPEPCACNA2D1CACNB3 | |
| SCHEMBL8072286 | 0.78 | LAP3 (0.48) | LAP3SLC7A5RNPEPCACNA2D1CACNB3 | |
| SCHEMBL30852968 | 0.77 | LAP3 (0.44) | LAP3SLC7A5RNPEPCACNA2D1CACNB3 | |
| SCHEMBL26940451 | 0.76 | LAP3 (0.47) | LAP3SLC7A5RNPEPCACNA2D1CACNB3 | |
| SCHEMBL19301334 | 0.76 | FOLH1 (0.50) | LAP3SLC7A5RNPEPCACNA2D1CACNB3 | |
| SCHEMBL7253641 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150148326-A1 | Monobactams | PFIZER (US) | 2015-05-28 | — | — | US | disclosed |
| EP-2646436-B1 | MONOBACTAMS | PFIZER (US) | 2015-05-27 | — | — | EP | disclosed |
| EP-2646436-A1 | MONOBACTAMS | Pfizer Inc (US) | 2013-10-09 | — | — | EP | disclosed |
| US-20130252935-A1 | Monobactams | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20120302542-A1 | MONOBACTAMS | PFIZER INC | 2012-11-29 | — | — | US | disclosed |
| WO-2012073138-A1 | MONOBACTAMS | PFIZER INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-4060691-A | 7-{3-Hydroxy-2-[4-hydroxy-4-(lower alkyl)-trans-1-octen-1-yl]-5-oxocyclopent-1-yl}heptanoic acids and esters | G. D. SEARLE & CO. (US) | 1977-11-29 | — | — | US | disclosed |
| US-3965143-A | 16-Oxygenated prostanoic acid derivatives | G. D. SEARLE & CO. (US) | 1976-06-22 | — | — | US | disclosed |
| US-3932496-A | Mono- and dialkylated prostynoic acid derivatives | G. D. SEARLE & CO. (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252935-A1 | Monobactams | MGAM, MGAM2, BPGM | LAP3 3547/4885SLC7A5 2421/4885RNPEP 1461/4885 |
| US-20150148326-A1 | Monobactams | MGAM, MGAM2, BPGM | LAP3 3547/4885SLC7A5 2421/4885RNPEP 1461/4885 |
| US-20120302542-A1 | MONOBACTAMS | MGAM, MGAM2, BPGM | LAP3 3547/4885SLC7A5 2421/4885RNPEP 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.